Amy Pointon is currently the Head of Cell and Gene Therapy Safety at AstraZeneca, where they previously held several significant roles, including Senior Director of Cardiovascular Safety and Associate Director of Cardiovascular Safety in Drug Safety and Metabolism from 2017 to 2021. They began their career in the field as a Post Doc Fellow in Molecular Toxicology and have advanced through various positions, including Senior Scientist and Associate Principal Scientist. Amy earned a Doctor of Philosophy (PhD) in Toxicology from the University of Leicester between 2006 and 2009.
This person is not in the org chart
This person is not in any teams
This person is not in any offices